Hospital Gregorio Marañón Develops Neuroprotective Eye Drops for Glaucoma
Researchers at Hospital General Universitario Gregorio Marañón are developing a neuroprotective eye drop to treat glaucoma, according to a hospital statement. The treatment uses cilastatin to protect retinal neurons and reduce inflammation, with the goal of initiating Phase I human clinical trials by 2027.
Glaucoma is a neurodegenerative disease of the retina that can cause progressive and irreversible vision loss. The hospital’s research team, collaborating with researchers from the Universidad Complutense de Madrid, developed this formulation after cilastatin showed effectiveness in animal models of the disease.
Why is this treatment different from current glaucoma drugs?
Most existing treatments focus on reducing intraocular pressure, which the hospital identifies as a primary risk factor. However, these drugs do not directly address the neurodegenerative component of the disease.
According to the hospital, more than 40% of patients do not respond to available medications. Additionally, 10% of patients develop total blindness within 7 to 15 years.
How was the neuroprotective eye drop developed?
The development relies on a new indication for cilastatin, a drug typically used in combination with antibiotics. Hospital officials stated the molecule demonstrated an ability to protect retinal neurons and modulate inflammation in experimental glaucoma models.
The project is currently moving through preclinical studies to ensure safety and efficacy. These studies are being managed by Telara Pharma, a spin-off company created from the hospital and its Sanitary Research Institute.
What happens next in the development process?
The research team must first complete the current preclinical stage. If these studies are successful, the hospital may begin Phase I clinical trials in 2027 to test the formulation’s efficacy in humans.
The ultimate goal is to demonstrate that this solution protects retinal neurons from progressive damage. This approach could eventually complement existing therapies to help preserve vision and improve patient quality of life.
Frequently Asked Questions
What drug is being used in the new eye drop?
The eye drop is based on cilastatin, a drug normally used with antibiotics that researchers found has neuroprotective and anti-inflammatory effects on the retina.
When will the treatment be tested on humans?
The hospital aims to start Phase I clinical trials in 2027, provided the current preclinical stages are completed.
Why are new glaucoma treatments necessary?
Current treatments only target intraocular pressure; they do not stop neurodegeneration. According to the hospital, over 40% of patients do not respond to these current drugs.
How do you think neuroprotective treatments could change the long-term outlook for patients with degenerative eye diseases?